View More Recent Stories
-
BridgeBio Pharma (BBIO) PT Lowered to $45 at Citi
-
BridgeBio Pharma Inc. (BBIO) Tops Q2 EPS by 41c
-
BridgeBio Pharma Inc. (BBIO) Appoints Thomas Trimarchi as COO
-
Raymond James on BridgeBio Pharma (BBIO): 'We expect the topline nominal win for HELIOS-B will send BBIO shares downward'
-
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
Evercore ISI on HELIOS-B Read-Through to BridgeBio Pharma (BBIO)
-
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
-
BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive Data
-
BridgeBio Pharma Inc. (BBIO) Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418
-
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)

